Institutional Financial, IFMI, Revenue increase, declares dividends. Red Giant, REDG,Giant Leap up 33%

Institutional Financial, IFMI, Reports 33% Revenue increase, declares dividends. Red Giant, REDG, takes a Giant Leap up 33%

Full Year Adjusted Operating Income of $7.5 million, or $0.47 per Diluted Share

Fourth Quarter Adjusted Operating Income of $4.3 million, or $0.26 per Diluted Share

Fourth Quarter Net Income of $4.1 million, or $0.26 per Diluted Share

Board Declares Dividend of $0.02 per Share

The Company noted that during the fourth quarter, net trading revenue increased $4.5 million, or 33%, from the prior quarter and increased $2.5 million, or 16%, from the year-ago quarter, despite the Company having substantially reduced its headcount and compensation expenses in its capital markets businesses.

“We are pleased with our performance in the fourth quarter, and believe that our full year results are especially meaningful when considering the adverse conditions we have worked to overcome, particularly in the first half of 2012,” said Daniel G. Cohen, Chairman and Chief Executive Officer of IFMI. “The fourth quarter was our second profitable quarter in a row at both the adjusted operating income and net income levels. In addition, we continued to work hard to control both our compensation and non-compensation costs across all of our operating segments. While market conditions remain difficult, we are encouraged by the progress made throughout our diverse operating units and our focus remains on increasing value for our shareholders.”

source: the company, OxBridge Research

VALV, Shengkai Innovations, XOMA, Xoma Ltd.

VALV – Shengkai Innovations makes ceramic valves and components for industrial. It provides ceramic valves in various categories, including gate valves, ball valves and adjustable cut-off valves.The company’s primary customers are electric power, petrochemical, chemical, aluminum, and metallurgy industries. The company is expected to increase its global market share. Stock is bouncing back from 52WK lows, keep an eye!

XOMA – XOMA is a biopharmaceutical company, engaged in the development of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on products, such as LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease.

XOMA products include HCD122, a human anti-CD40 antagonist antibody for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases in Phase I/II clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. Undervalued, Bouncing back from 52WK LOWS.

You are missing the Premium Alerts! Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks